EMMA · Emmaus Life Sciences, Inc.
$0.03
+0.01 (+22.99%)
At close · Aug 21
Going-concern doubt
— flagged Aug 14, 2026
Substantial doubt about the company's ability to continue as a going concern.
“Because the Company's existing cash balance and anticipated cash flows cannot satisfy its current debt and ongoing obligations, combined with the uncommitted nature of the Company's financing plans, there is substantial doubt about the Company’s ability to continue as a going concern for 12 months from the date that these condensed consolidated financial statements are issued.”View the 10-Q filed Aug 14, 2026
Market Cap
$2.25M
Shares
70.19M
Named-executive compensation from the company's DEF 14A proxy statements — salary, bonus, stock and option awards, non-equity incentive, and the company-reported total per executive per fiscal year, exactly as disclosed in the Summary Compensation Table.
Fiscal 2021
| Executive | Role | Total |
|---|---|---|
| Yutaka Niihara | M.D., MPH Chairman of the Board and Chief Executive Officer | $484,203 |
| Yasushi Nagasaki | Chief Financial Officer | $350,000 |
| Willis C. Lee | M.S. Chief Operating Officer | $340,000 |
Fiscal 2020
| Executive | Role | Total |
|---|---|---|
| Yutaka Niihara | M.D., M.P.H. Chairman and Chief Executive Officer | $385,000 |
| Yasushi Nagasaki | Chief Financial Officer | $240,000 |
| Willis C. Lee | Chief Operating Officer | $240,000 |
Fiscal 2019
| Executive | Role | Total |
|---|---|---|
| Yutaka Niihara | M.D., M.P.H. Chairman and Chief Executive Officer | $385,000 |
| Willis C. Lee | Chief Operating Officer | $240,000 |
| Yasushi Nagasaki | Chief Financial Officer | $235,000 |